Why Valeant Pharmaceuticals Intl Inc. Will Fail to Re-Invent Itself

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) had a horrible year, and I believe the stock is far from rallying.

| More on:
The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) had an abysmal year as the stock plummeted 86%. The company wants to re-invent itself to become a dominant player in the pharmaceutical scene again.

There were huge changes made this year as ex-CEO Michael Pearson stepped out and Joseph Papa stepped in. Joseph Papa is an excellent choice as the new CEO, and he’s got a ton of incentive to bring the company out of the gutter, but I believe he’s in way over his head. Valeant has severely damaged its reputation with investors across the globe, and I don’t believe anything can reverse what has already happened.

As Warren Buffett once said, “It takes 20 years to build a reputation and five minutes to ruin it.”. To say Valeant’s reputation has been ruined is an understatement.

The company has faced so many scandals and endured so many short attacks that even the most contrarian of investors are avoiding this stock like the plague. Charlie Munger, Warren Buffett’s right-hand man, even went as far as to call the company a “sewer.” These are strong words put forth by the guru, but I believe he’s right on the spot with his statement.

There are many contrarian investors that are looking to gain a quick profit by trying to get into Valeant. But there doesn’t appear to be a bottom, and the upside may be limited considering the company’s ruined reputation.

Activist investor Bill Ackman is now on the board of directors, and he’s still fully invested, even after the massive decline the stock faced over the past year and a half. Don’t follow Ackman into this one. Most of his original investment is already gone, and he’s just trying to recover some of his losses, but I don’t believe he’ll be successful.

Valeant still has $8 billion worth of debt and will need to sell its non-core assets at a loss. Buying high and selling low is never a good strategy to make money, and I believe the company will remain on damage control for the next few years before the stock can start moving higher.

Even if you’re a believer in Bill Ackman and the new CEO Joseph Papa, any upside in 2017 will be very modest, and there’s still the risk of a further correction as more disappointing earnings reports come in. There is also the risk of having more scandals should there be any shady findings from investigations going forward.

If you’re a contrarian investor, then steer clear of Valeant. Its reputation is permanently damaged, and it’s not going to soar anytime soon. There’s still a huge mess that Michael Pearson left, and it won’t be cleaned up anytime soon.

I have one simple rule. If there’s any sign of shady activity in a company’s history, then that makes the stock an automatic sell. Don’t even think about picking up share in Valeant unless you’re willing to lose it all.

Fool contributor Joey Frenette has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Hourglass and stock price chart
Energy Stocks

Two High-Yield Dividend Stocks You Can Buy and Hold for a Decade

These companies have increased their dividends annually for decades.

Read more »

Piggy bank and Canadian coins
Dividend Stocks

Canadians: Here’s How Much You Need in Your TFSA to Retire

If you hold Fortis Inc (TSX:FTS) stock in a TFSA, you might earn enough dividends to cover part of your…

Read more »

The TFSA is a powerful savings vehicle for Canadians who are saving for retirement.
Investing

TFSA Season is Here: Canadian Stocks Worth Holding Tax-Free All Year

Investors should focus on total returns in their TFSA whether their focus is on income, growth, or a combination of…

Read more »

Nuclear power station cooling tower
Metals and Mining Stocks

How to Invest in Uranium as a Canadian in 2026

This ETF provides exposure to spot uranium prices and uranium miners.

Read more »

Oil industry worker works in oilfield
Energy Stocks

Canadian Investors: Should You Buy Canadian Natural Resources Stock While Under $45?

Is the Venezuela scare a threat or an opportunity? Here is why Canadian Natural Resources (TSX:CNQ) stock looks like a…

Read more »

Child measures his height on wall. He is growing taller.
Investing

2 Brilliant Growth Stocks to Buy Now and Hold for the Long Term

Agnico Eagle Mines (TSX:AEM) and another Canadian stock worth buying right here.

Read more »

e-commerce shopping getting a package
Tech Stocks

2 Laggards With High Upside Potential on the TSX Today

Given their long-term growth opportunities and discounted valuation, these two underperforming TSX stocks can deliver superior returns.

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

1 Ideal TFSA Stock Paying 7% Income Every Month

A TFSA can feel like payday with a monthly payer like SmartCentres, but the real “winner” test is cash flow…

Read more »